C David Adair
MD
Regular (MFM)
Member Since: 1996
Professional Bio
Dave (“Mugsy”) Adair, M.D., MBA Co-Founded Solas BioVentures based upon the desire to bring needed innovation to the patient’s bedside. This patient centric focus came from his long academic medical career providing care and solutions to leverage the healthcare equation of Value = Quality /Cost. He has operated a startup MedTech, co-founded a large regional medical specialty group, as well as grown angel investing into a venture capital firm. Life Science Tennessee Association Board previously.
He is a widely published author with over 100 published articles and a frequent speaker to academic venues throughout the U.S. and E.U. He retired as professor emeritus from the University of Tennessee College of Medicine in the Department of Obstetrics and Gynecology, but currently enjoys Locum work. His prior board experience is notable for Veran Medical acquired by Olympus Medical, NxThera acquired by Boston Scientific, Aegea Medical (Chair) acquired by Cooper Surgical, Aerial BioPharma acquired by Jazz Pharmaceuticals, Knopp biosciences acquired by Biohaven and a stand-alone spin out, Aretia Therapeutics. Dave currently serves on the board of Arrivo BioVentures, Francis Medical, Intershunt Technologies, NX Prenatal, Stimdia Medical, Inc., and Vesalio.
Dave earned a BS in Biology from Morehead State University, where he is in the Alumni Hall of Fame. A medical doctorate from The Joan C Edwards School of Medicine of Marshall University, where he was recognized as the Distinguished Alumnus in 2020. He completed his residency in Obstetrics & Gynecology from The University of Florida, and fellowship training in Maternal Fetal Medicine from Wake Forest University and earned the first Healthcare MBA from The Gary W. Rollins College of Business of The University of Tennessee Chattanooga. He is triple board certified in Obstetrics & Gynecology, Maternal Fetal Medicine, and Hypertension.
He is a widely published author with over 100 published articles and a frequent speaker to academic venues throughout the U.S. and E.U. He retired as professor emeritus from the University of Tennessee College of Medicine in the Department of Obstetrics and Gynecology, but currently enjoys Locum work. His prior board experience is notable for Veran Medical acquired by Olympus Medical, NxThera acquired by Boston Scientific, Aegea Medical (Chair) acquired by Cooper Surgical, Aerial BioPharma acquired by Jazz Pharmaceuticals, Knopp biosciences acquired by Biohaven and a stand-alone spin out, Aretia Therapeutics. Dave currently serves on the board of Arrivo BioVentures, Francis Medical, Intershunt Technologies, NX Prenatal, Stimdia Medical, Inc., and Vesalio.
Dave earned a BS in Biology from Morehead State University, where he is in the Alumni Hall of Fame. A medical doctorate from The Joan C Edwards School of Medicine of Marshall University, where he was recognized as the Distinguished Alumnus in 2020. He completed his residency in Obstetrics & Gynecology from The University of Florida, and fellowship training in Maternal Fetal Medicine from Wake Forest University and earned the first Healthcare MBA from The Gary W. Rollins College of Business of The University of Tennessee Chattanooga. He is triple board certified in Obstetrics & Gynecology, Maternal Fetal Medicine, and Hypertension.